Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia
Explore this paper's citation graph
Summary
Pravastatin and bezafibrate proved significantly more effective in the management of HAART-related hyperlipidaemia than the switching therapy from PI to nevirapine or efavirenz.
- Type
- article
- Published
- 2005-07-01
- Cited by
- 120
- References
- 49
- OpenAlex
- https://openalex.org/W1964344610
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:8731385
Keywords
Nevirapine, Efavirenz, Pravastatin, Medicine, Lamivudine
References
- Coronary artery calcification, atherogenic lipid changes, and increased erythrocyte volume in black injection drug users infected with human immunodeficiency virus-1 treated with protease inhibitors.
- Lipid lowering effects of statins and fibrates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practice.
- The nephrotic syndrome.
- Long-term cardiovascular risk with protease inhibitors and management of the dyslipidemia.
- Protease inhibitor therapy-associated lipodystrophy, hypertriglyceridaemia and diabetes mellitus.
- Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men
- Acute Pancreatitis as a Complication of Ritonavir Therapy in a Patient with AIDS
- Pilot study of coronary atherosclerotic risk and plaque burden in HIV patients: 'a call for cardiovascular prevention'.
- Hyperlipidemia and Insulin Resistance Are Induced by Protease Inhibitors Independent of Changes in Body Composition in Patients With HIV Infection
- Marked hypertriglyceridaemia associated with ritonavir therapy.
- Use of Fibrates in the Management of Hyperlipidemia in HIV-Infected Patients Receiving HAART
- Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy.
- Meta-analysis of randomized controlled trials of simplified versus continued protease inhibitor-based antiretroviral therapy in HIV-1-infected patients
- Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors.
- Coronary artery disease and human immunodeficiency virus infection.
- Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study.
- Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART
- Metabolic Disorders Among HIV‐Infected Patients Treated With Protease Inhibitors: A Review
- Atherosclerosis in AIDS: potential pathogenetic roles of antiretroviral therapy and HIV.
- Stroke in HIV-Infected Patients: A Clinical Perspective
Cited by
- HIV and Antiretroviral Therapy: Lipid Abnormalities and Associated Cardiovascular Risk in HIV-Infected Patients
- Intervenção nutricional previne alterações do perfil lipídico em indivíduos HIV-Positivo que iniciam terapêutica anti-retroviral : um ensaio clínico randomizado
- Management of metabolic complications and cardiovascular risk in HIV-infected patients.
- Insulin Resistance, Glucose Intolerance and Diabetes Mellitus in HIV-Infected Patients
- Kidney failure during HIV disease treated with tenofovir, multiple concurrent diseases and drug therapies
- The Role of Statins in the Setting of HIV Infection
- Non‐nucleoside reverse transcriptase inhibitors: a review
- Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction.
- Management of dyslipidemia in HIV infected patients on combined antiretroviral therapy : effects of intervention
- Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men—a randomized, placebo-controlled study
- Evaluation of nevirapine‐switch strategies for HIV treatment
- Cardiovascular risk and choice of HIV drug regimen
- Therapy Insight: body-shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy
- Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108
- Coronary heart disease in people infected with HIV
- Hypertriglyceridemia: its etiology, effects and treatment
- Whether to Retest the Lipids of HIV-Infected Patients: How Much Does Fasting Bias Matter?
- Management of antiretroviral drug toxicity
- Effectiveness of lipid-lowering therapy in HIV patients
- Effectiveness and Tolerability of Oral Administration of Low-Dose Salmon Oil to HIV Patients with HAART-Associated Dyslipidemia
Related papers
- Long-term effectiveness of first-line non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy in Ghana.
- A Comparison of Methods for Measuring Rectal HIV Levels Suggests that HIV DNA Resides in Cells other than CD4+T Cells, Including Myeloid Cells
- Virologic Response to First-Line Efavirenz- or Nevirapine-Based Anti-Retroviral Therapy in HIV-Infected African Children
- Plasma Drug Concentrations and Virologic Evaluations after Stopping Treatment with Nonnucleoside Reverse-Transcriptase Inhibitors in HIV Type 1–Infected Children
- The Nonnucleoside Reverse Transcriptase Inhibitors Efavirenz and Nevirapine in the Treatment of HIV
- Assessment of Drug-Drug Interactions Between Tenofovir Disoproxil Fumarate and the Nonnucleoside Reverse Transcriptase Inhibitors Nevirapine and Efavirenz in HIV-Infected Patients
- Is it safe to switch between efavirenz and nevirapine in the event of toxicity?
- Efavirenz and Nevirapine in HIV-1 Infection
- Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors.
- [The use of the non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz in the treatment of patients with a chronic HIV-I infection].